Related Experiment Video
Updated: Sep 26, 2026

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
Published on: September 13, 2022
Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension
Stefano Taddei1, Agostino Virdis, Lorenzo Ghiadoni
1Department of Internal Medicine, University of Pisa, Via Roma, 67, 56100 Pisa, Italy. s.taddei@int.med.unipi.it
Insights
Essential hypertension impairs blood vessel dilation due to oxidative stress. Lercanidipine treatment improved vasodilation by restoring nitric oxide (NO) availability and reducing oxidative stress, likely through antioxidant effects.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Oxidative Stress Research
Background:
- Essential hypertension is linked to reduced endothelium-dependent vasodilation.
- Oxidative stress contributes to nitric oxide (NO) breakdown in hypertension.
- Compensatory hyperpolarizing factors may play a role in hypertensive vasodilation dysfunction.
Purpose of the Study:
- To investigate if calcium antagonist treatment can restore NO availability and prevent hyperpolarization.
- To assess the antioxidant properties of calcium antagonists in essential hypertension.
- To evaluate the effects of lercanidipine on endothelium-dependent vasodilation and oxidative stress markers.
Main Methods:
- Forearm blood flow was measured using strain-gauge plethysmography in healthy controls and hypertensive patients.
- Intrabrachial infusions of bradykinin, NG-monomethyl-l-arginine (L-NMMA), and ouabain were used to assess vasodilation.
- The effects of antioxidant vitamin C and 3-month lercanidipine treatment were evaluated.
- Plasma levels of oxidative stress markers (lipoperoxides, isoprostanes, malondialdehyde) and antioxidant capacity were measured.
Main Results:
- Hypertensive patients showed blunted bradykinin-induced vasodilation, resistant to L-NMMA but sensitive to ouabain.
- Vitamin C improved vasodilation in hypertensive patients and restored L-NMMA's inhibitory effect.
- Lercanidipine treatment reduced oxidative stress markers and improved vasodilation.
- Lercanidipine restored L-NMMA's inhibitory effect and prevented ouabain's effect, with vitamin C losing its facilitating activity post-treatment.
Conclusions:
- Lercanidipine enhances endothelium-dependent vasodilation in essential hypertension.
- The beneficial effects of lercanidipine are attributed to restored NO availability and prevention of hyperpolarization.
- Antioxidant activity is likely the primary mechanism underlying lercanidipine's therapeutic effects in hypertensive patients.
Abstract:
Essential hypertension is associated with impaired endothelium-dependent vasodilation caused by oxidative stress-induced nitric oxide (NO) breakdown and compensatory production of a hyperpolarizing factor. To test whether calcium antagonist treatment can restore NO availability and prevent hyperpolarization through antioxidant properties, in 15 healthy subjects and 15 patients with essential hypertension, we studied forearm blood flow (strain-gauge plethysmography) modifications induced by intrabrachial bradykinin (5, 15, 50 ng/100 mL per minute), an endothelium-dependent vasodilator, in basal conditions, during infusion of NG-monomethyl-l-arginine (L-NMMA, 100 microg/100 mL per minute), an NO-synthase inhibitor, and ouabain (0.72 microg/100 mL per minute), an Na+-K+ ATPase inhibitor to prevent hyperpolarization. These infusions were repeated in the presence of the antioxidant vitamin C (8 mg/100 mL/min). The response to sodium nitroprusside was also evaluated. In controls, vasodilation to bradykinin was inhibited by L-NMMA and remained unchanged by ouabain or vitamin C. In hypertensive patients, vasodilation to bradykinin was blunted and resistant to L-NMMA but sensitive to ouabain. Vitamin C increased the response to bradykinin and restored the inhibiting effect of L-NMMA while preventing the effect of ouabain. In hypertensive patients, infusions were repeated after 3-month treatment with lercanidipine (10 to 20 mg daily). Lercanidipine decreased plasma lipoperoxides, isoprostanes, and malondialdehyde and increased plasma antioxidant capacity. Moreover, lercanidipine increased the vasodilation to bradykinin and restored the inhibiting effect of L-NMMA on bradykinin-induced vasodilation while preventing the effect of ouabain. Finally, vitamin C no longer exerted its facilitating activity. These results indicate that in essential hypertension, lercanidipine increases endothelium-dependent vasodilation by restoring NO availability and preventing hyperpolarization, an effect probably determined by antioxidant activity.
Related Concept Videos
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antihypertensive Drugs: Potassium-Sparing Diuretics
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Hypertension IV: Drug Therapy and Lifestyle Modifications
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System